Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies - Concepedia

Concepedia

Publication | Open Access

Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies

DOI Full Paper Access

147

Citations

25

References

2022

Year

Patrick Schöffski, Daniel Shao-Weng Tan, Miguel Martín, María Ochoa-de-Olza, John Sarantopoulos, Richard D. Carvajal, Chrisann Kyi, Taito Esaki, Amy Prawira, Wallace Akerley,

Journal for ImmunoTherapy of Cancer

Abstract

NCT02460224.

References

	Year	Citations

Page 1